Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Particulate form
Patent
1995-04-18
1996-12-10
Azpuru, Carlos
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Particulate form
424423, 424451, 424464, 424474, 514937, A61F 202, A61K 914, A61K 920, A61K 948
Patent
active
055828396
ABSTRACT:
A magnesium-taurine compound and its method of synthesis. the compound is synthesized by reacting taurine and magnesium in a 2:1 molar ratio. The resulting mixture is diluted with methanol and the remaining clear filtrate is crystallized from methanol. This compound may be administered orally as a nutritional supplement or may be administered orally or intravenously for the therapeutic or prophylactic treatment of acute cardiac conditions.
REFERENCES:
patent: 3725553 (1973-04-01), Giotti et al.
B. M. Altura et al. (1984) Magnesium, electrolyte transport and coronary vascular tone. Drugs 28 (Suppl. 1):120-142.
T. W. Anderson et al. (1975) Ischemic heart disease, water hardness and myocardial magnesium. CMA Journal 113:199-203.
S. E. Atahanov et al. (1992) Modulation of receptor-dependent increase of calcium ions in human platelets by taurine. Arzneim.-Forsch./Drug Res. 42(11):1311-1313.
J. Azuma et al. (1983) Double-blind randomized crossover trial of taurine in congestive heart failure. Current Therap. Res. 34(4):543-557.
T. Dyckner et al. (1983) Effect of magnesium on blood pressure. Brit. Med. Jour. 286:1847-1848.
K. R. Gei.beta. et al. (1994) The effect of a taurine-containing drink on performance in 10 endurance-athletes. Amino Acids 7:45-56.
K. C. Hayes et al. (1989) Taurine modulates platelet aggregation in cats and humans.sup.1-3. Am. J. Clin. Nutr. 49-1211-1216.
R. J. Huxtable (1992) Physiological actions of taurine. Physiological Reviews 72(1):101-163.
L. T. Iseri (1984) Magnesium in coronary artery disease. Drugs 28 (Suppl. 1):151-160.
T. Motoyama et al. (1989) Oral magnesium supplementation in patients with essential hypertension. Hypertension 13(3):227-232.
M. A. Petty et al. (1990) The effects of taurine on atherosclerosis development in cholesterol-fed rabbits. European Jour. of Pharmacology 180:119-227.
M. P. Ryan et al. (1984) The role of magnesium in the prevention and control of hypertension. Ann. Clin. Res. 16:81-88.
S. W. Schaffer et al. (1994) Mechanisms underlying physiological and pharmacological actions of taurine on myocardial calcium transport. Taurine in Health and Disease 171-180.
S. W. Schaffer et al. (1990) Regulation of calcium homeostasis by taurine: role of calmodulin. Taurine: Functional Neurochemistry, Physiology, and Cardiology 217-225.
M. S. Seelig et al. (1974) Magnesium interrelationships in ischemic heart disease: a review. The Amer. Jour. of Clin. Nutrition 27:59-79.
M. Shechter et al. (1992) The rationale of magnesium supplementation in acute myocardial infarction. Arch. Intern. Med. 152:2189-2196.
K. Yamauchi-Takihara et al. (1986) Taurine protection against experimental arterial calcinosis in mice. Biochemical and Biophysical Research Communications 140(2):679-683.
Azpuru Carlos
Nutrition 21
LandOfFree
Magnesium taurate and other mineral taurates does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Magnesium taurate and other mineral taurates, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Magnesium taurate and other mineral taurates will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-422228